The aim of this study was to assess the clinical evidence for platinum-Taxol non-cross-resistance in patients with epitheli ovarian cancer. Unlike other studies, only patients who had demonstrably progrive disease on platinum therapy were analysed. Patients received 135-200 mg m-2 of Taxol over 3 or 24 h and all patients were assessed for response by computerised axial tomography. The overall response rate was 22.2% (8/36 patients, 95% CI 10-39%). Only patients who received > 175 mg m-2 of Taxol responded (26.7%; 8/30 patients, 95% CI 12-46%). No complete responses were seen and the duration of response was short, median 7 months (range 5-9+). Response was associated with a short treatment-free interval (P=0.02); only those who were treated immediately after they had progd on their previous platinum therapy responded. Response duration was associated with a good performance status (P<0.05). Platinum and Taxol are non-cross-resistant in a proportion of patients and therefore patients who are resistant to platinum compounds may benefit from Taxol although the duration of any response is short These data support current strategies that involve combining Taxol with platinum compounds as first-line therapy in advanced epithelial ovarian cancer.
Taxol was first isolated from the bark of the Pacific yew (Taxus brevifolia) in 1971 (Wani et al., 1971) and has since been shown to have a wide spectrum of biological activity (Slichenmeyer and Von Hoff, 1991) but its main antineoplastic effect appears to be the promotion of polymerisation of microtubules, resulting in the formation of stable nonfunctional microtubules (Schiff et al., 1979) . The drug is active in patients with relapsed epithelial ovarian cancer, and cumulative data suggest that the response rate in this group of patients is 13-50% (McGuire et al., 1989; Thigpen et al., 1990; Enzig et al., 1992; Sarosy et al., 1992; Swenerton et al., 1993) . However, one of the most important considerations in the design of phase II studies in relapsed ovarian cancer is patient sekction with regard to previous treatment. It is now well established that patients are more lily to respond to second-line chemotherapy the longer the time interval between the end of treatment and their relapse (Blackledge et al., 1989; Gore et al., 1990; Markman et al., 1991) . The importance of patient seection is even greater when evaluating whether or not a new compound is cross-resistant to standard therapy. Trimble et al. (1993) have demonstrated that Taxol is active in patients with poor-prognosis relapsed epithelial ovarian cancer. Their study included patients who had responded to platinum-based chemotherapy and relapsed within 3 months as well as patients with truly platinumrefractory disease, i.e. progressing while on platinum. They did not, however, address the issue of Taxol-platinum noncross-resistae and its true incidence has not been studied. Non-cross-resistance can only be confidently reported in a population of patients that have truly platinum-refractory disease and that can only be definitely assessed in the presence of measurable progressive disease while the patient is receiving platinum-based chemotherapy. We present here our experience of Taxol given to a group of patients that have truly platinum-refractory disease and thus report the clinical evidence for, and incidence of, Taxol-platinum non- Tables I and II. Patients could only enter these studies if they had histologically proven epithelial ovarian cancer, ECOG status of 0-2, absolute granulocyte count < 1.5 x 1091-', platelet count > 100 x 1091', bilirubin < 2 x upper limit of normal and creatinine S 2 x upper limit of normal. Patients were excluded if they had serious, inadequately controlled cardiac dise, pre-existing peripheral neuropathy > grade 2 or were known to have an allergic reaction to drugs containing Cremophor. All patients gave written informed consent according to guidelines laid down by the Royal Marsden Hospital Ethics Committee. Statistical methods Exact confidence intervals on response rates are quoted. Duration of response was measured from the date of the first treatment to the date progression and was confirmed by computerised axial tomography. We examined a number of patient characteristics to assess their role as predictors of response and response duration using log-rank analysis (Taxol dose, histology, age, performance status, haemoglobin, treatment-free interval, number of disease sites, size of largest deposit).
Redts
The overall response rate was 22.2% (8/36, 95% Ca 10-39%) but no patient responded to 135 mg mi2 Taxol (0/6) whereas 26.7% (8/30, 95% Cl 12-46%) patients responded to > 175mgmn2 Taxol. All patients received 1-10 cycles (median 3) of Taxol, with responders receiving 6-10 cycles (median 8). The median duration of response was 7 months (range 5-9 + ). All but three patients relapsed while on treatment; two patients developed disease progression 2 and 3 months after stopping Taxol and one patient who has just completed treatment remains in PR at 9 + months. There were no responses in the six patients who were resistant to combination platinum-based chemotherapy or in the six patients who had previously received > 3 prior treatments. Seven patients had stabilisation of their disease lasting 1-12 +months (median 4). The median survival for all 36 patients analysed was 26 weeks (range 2-117). Response was associated with the treatment-free interval; all responders were in the group of patients treated immediately after progressing on platinum therapy (8/20, P = 0.02). There was also is notoriously inaccurate and we wanted to be absolutely sure that the patients being assessed for Taxol-platinum noncross-resistance were truly platinum refractory.
Our study demonstrates that Taxol and platinum are noncross-resistant in 26.7% of patients when doses of > 175 mgm2 Taxol are used. These data suggest that it is logical to combine Taxol with platinum compounds as firstline therapy for treatment of epithelial ovarian cancer. However, the development of Taxol resistance appears surprisingly quickly. All but two of the responders relapsed while on treatment and the median duration of response was only 7 months (range 5-9 + ). The two patients who relapsed off treatment did so at 2 and 3 months after stopping Taxol. A careful assessment of the symptomatic benefit that is likely to be derived from using Taxol in a platinum-refractory patient needs to be weighed against cost and toxicity.
All our patients were resistant to carboplatin and therefore our data mainly relate to carboplatin-Taxol cross-resistance.
Plinu-Tazol _nonoss-resistac in wraruan canoer wi ME Gore et al 1310 However, we have previously shown that there is crossresistance between carboplatin and cisplatin in most patients (Gore et al., 1989) , and we can therefore extrapolate our data to suggest that it is likely that Taxol and cisplatin are noncross-resistant in at least a proportion of patients. These data support the current strategies exploring combinations of Taxol and platinum compounds as first-line therapy for advanced epithelial ovarian cancer.
